Sergio Storti

Sergio Storti

Auto-generated profile, based on publicly available information

Sergio Storti

UOC Oncoematologia Fondazione di Ricerca e Cura Giovanni Paolo II, Campobasso - Università Cattolica del Sacro Cuore, Campobasso, Italy

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
SBSara Bringhen
Sara Bringhen
MOMassimo Offidani
Massimo Offidani
SPSalvatore Palmieri
Salvatore Palmieri
FPFrancesco Pisani
Francesco Pisani
RRRita Rizzi
Rita Rizzi
Alessandra LaroccaAlessandra Larocca
Alessandra Larocca

1 January 1995 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PZPier Luigi Zinzani
Pier Luigi Zinzani
MMM. Martelli
M. Martelli
SSS. Storti
S. Storti
MMM. Musso
M. Musso
MCM. Cantonetti
M. Cantonetti
STS. Tura
S. Tura
Until now, literature data support the fact that the CHOP regimen represents the standard first line treatment for patients with advanced intermediate-grade non-Hodgkin's lymphoma. Recently, idarubicin has been introduced in clinical trials because of its favourable preclinical profile: it is more active than daunorubicin and doxorubicin against a number of experimental tumour systems and is significantly less cardiotoxic in animal models. From March 1991 to June 1993, 115 previously untreated patients with stage II to IV intermediate-grade non-Hodgkin's lymphoma, according to the Kiel classification, were enrolled in a phase III comparative trial. The objectives of the study were to compare the efficacy and safety of using idarubicin instead of doxorubicin in the polychemotherapeutic regimen CHOP (cyclophosphamide, doxorubicin, vincristine, and dexamethasone). Of the 115 patients registered for the trial, 103 were evaluable: 52 received CH (doxorubicin)OP and 51 received CI(Idarubicin)OP. Known prognostic factors were equally distributed among the two groups. There were no significant differences between the 2 groups in the rates of partial and complete response. The overall response rate was 87%, with complete response in 62%: 63% in the CHOP group, and 59% in the CIOP group. At 30 months (median 20 months), 86% of all CR patients were alive without disease in the CHOP group and 85% in the CIOP group. Patients treated with CHOP experienced severe alopecia more frequently (P = .004). Only three patients in the CIOP group showed cardiac adverse events (1 moderate and 2 mild), while in the CHOP group 4 mild, 2 moderate and 1 severe were recorded. LVEF monitoring was carried out in 31 patients of the CHOP group and in 27 of the CIOP group. A median drop of 8.3% of the LVEF was observed in patients treated with CHOP regimen as compared to 4.8% in patients with CIOP regimen (P = .0001). In this trial, the "idarubicin arm" (CIOP regimen) was found to have an equivalent therapeutic efficacy and, slightly, reduced clinical toxicity in comparison to the standard doxorubicin-containing CHOP regimen in patients with intermediate-grade non-Hodgkin's lymphoma.

16 November 2012 in Blood
Verified
Journal Article
Open access
LRLuigi Rigacci
Luigi Rigacci
Umberto VitoloUmberto Vitolo
Umberto Vitolo
MCMaria Christina Cox
Maria Christina Cox
LDLiliana Devizzi
Liliana Devizzi
AFAlberto Fabbri
Alberto Fabbri
PZPier Luigi Zinzani
Pier Luigi Zinzani
Abstract 3694 Based on published favorable Phase 2 data in patients with relapsed/refractory non Hodgkin Lymphoma (NHL)(Wiernik, 2008), the Italian Drug Agency (AIFA) granted the nulla osta to patients with NHL who were ineligible to receive more intensive curative treatments, which allowed off-label treatment with lenalidomide on a case by case basis. From April 2008 to December 2010, 180 NHL patients, most of them diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) and Mantle Cell Lymphoma (MCL), were treated with lenalidomide. All patients were tracked in an ad hoc database, in order to ensure compliance with the Risk Management Plan (RMP) already in place for the authorized use of lenalidomide in the multiple myeloma indication. Data collected from this cohort of NHL patients were retrospectively analyzed, with the aim to assess the safety and efficacy of lenalidomide administered to a heavily pretreated patient population in the context of routine clinical practice. To our knowledge, this is the largest NHL patient cohort treated with lenalidomide outside of a clinical trial. Data on 157 patients from 44 Italian sites have been collected and analyzed to date. Patient demographics and disease characteristics were as follows: median age 70 years (range 19–92); median number of prior treatments 3 (range 1–17); 94% of patients previously treated with rituximab. The lymphoma subtypes included DLBCL in 44%, MCL in 35%, Follicular Lymphoma (FL) in 9% and Transformed Lymphoma (TL) in 6% of cases. As expected, 62% of patients had Stage IV disease, in keeping with the highly unfavorable characteristics of a heavily pretreated patient population. In the majority of treatment cycles, lenalidomide was administered at a dose of 25 mg (61%) and in combination (58%). Analyzing all cycles, dexametasone was the preferred drug combined with lenalidomide (35%), while rituximab was added in 10%. Median number of administered lenalidomide cycles was 3 (range 1–27). According to the International Workshop on Lymphoma Response Criteria 42 % of patients responded, with 18% CR + CRu and 24 % PR. The breakdown of overall responses according to the different lymphoma subtypes shows: a rate of 45%, 39%, 54%, and 33% in DLBCL, MCL, FL, and TL patients, respectively. Median duration of response was 7.8 months overall, 14.2 months specifically for patients who achieved CR/CRu. Median TTP and PFS are 7.8 and 5.7 months (Figure 1) respectively, and median OS 21.8 months (Figure 2). The safety and tolerability profile of lenalidomide appears to be comparable to what was already known from published clinical trial results in NHL (Wiernik et al., JCO 2008, Habermann et al., BJH 2009, Witzig et al., Ann of Onc 2011, Zaja et al., Haematol 2011, Zinzani et al., Clin Lymph Myel Leuk 2011, Wang et al., Lancet Onc 2012). No secondary neoplasms have been reported to date. In conclusion, with the limitations of a retrospective data collection, this analysis provides intriguing results on the use of an immunomodulatory drug such as lenalidomide in a large cohort of heavily pretreated NHL patients, who have limited therapeutic options or who are ineligible for more intensive curative treatments. In this very unfavorable patient setting, lenalidomide has shown incouraging response rates as well as PFS and OS values, suggesting anti-lymphoma activity.